NCT07003451
Novel Biomarkers in Assessment of Interstitial Lung Disease Associated With Rheumatoid Arthritis Patients
Not Yet Recruiting · Not specified · Assiut University · registry updated 2025-08-28
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
\- Assess Krebs von den Lungen-6 (KL-6) and Calprotectin as novel biomarkers for diagnosis of ILD among Rheumatoid arthritis patients
Inclusion
- Confirmed diagnosis of Rheumatoid arthritis, age \> 18 years.
Exclusion
- Patients who refuse to participate in the study,
- Patients with evidence of worsening or exacerbation of RA over the previous 6 months,
- concomitant diagnosis of an active neoplasia, or
- patients who had previously received radiotherapy,
- End organ failure.